Pivotal Trial of the Boomerang Catheter for PDVA

Not Applicable

• Conditions: Chronic Limb-Threatening Ischemia
• Interventions: Device: Boomerang Catheter

• Registration Number: NCT06311773
• Lead Sponsor: Aveera Medical, Inc.

Brief Summary

The purpose of this study is to establish the safety and effectiveness of the Boomerang Catheter for percutaneous Deep Venous Arterialization (pDVA) to treat no-option Chronic Limb-Threatening Ischemia.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-03-08
• Study First Submitted QC: 2024-03-08
• Study First Posted: 2024-03-15
• Study Start: 2024-04-16
• Status Verified: 2025-01
• Last Update Submitted: 2025-01-27
• Last Update Posted: 2025-01-28
• Primary Completion: 2026-03-31
• Study Completion: 2029-03-31

Recruitment & Eligibility

• Status: ENROLLING_BY_INVITATION
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

1. Patient is age ≥ 18 years

2. Patient has confirmed clinical diagnosis of Rutherford Category (RC) 5 or 6 Chronic Limb-Threatening Ischemia (CLTI) with previous angiogram or hemodynamic evidence (e.g., ABI ≤ 0.39, TP / TcPO2 < 30 mm Hg) demonstrating severely diminished arterial perfusion of the index limb.

3. Assessment by the PI and an Independent Review Committee (IRC) determines that patient has no option for conventional distal bypass, surgical or endovascular therapy for limb salvage.

4. Inflow artery criteria:

   • Imaging confirmation of patent inflow artery (< 50% stenosis) from Aortic bifurcation to tibial trifurcation.

5. Target conduit vein criteria:

   • Duplex ultrasound confirms that vein is free from thrombus, contiguous from the intended anastomosis site through the lateral plantar vein, and ≥ 2.0mm lumen-lumen diameter (with tourniquet applied) throughout.

6. Patient may be scheduled for a planned minor amputation (toe, ray, or trans-metatarsal) within 30 days after index procedure.

7. Prior stent(s) to inflow arteries (i.e., Iliac, SFA, Popliteal) are allowed.

8. Patient is willing and able to provide written informed consent.

9. Patient meets institutional criteria for procedure clearance and is able to comply with study requirements per PI judgement.

10. Diabetic patients have adequate glycemic control per investigator judgement.

11. Female patients of childbearing potential have a negative pregnancy test within 7 days prior to index procedure (urine)

12. Patient is enrolled in a wound care network and has an adequate support network to ensure compliance with medication regimen and follow-up study visits.

13. PI determines that the primary wound is stable (e.g., not rapidly deteriorating or showing signs of healing).

Exclusion Criteria

1. Life expectancy < 12 months.
2. Patient has a lower extremity vascular disease that may inhibit the procedure and/or jeopardize wound healing (e.g., vasculitis, Buerger's disease, significant edema in the target limb, deep venous thrombus in the target vein, hyperpigmentation, or medial ulceration above the ankle).
3. Patient is dialysis dependent.
4. Significant acute or chronic kidney disease with a serum creatinine of > 2.5 mg/dl in patients not undergoing dialysis.
5. Prior peripheral arterial bypass procedure on index limb within 30 days.
6. Previous major amputation of the target limb or absence of adequate viable tissue for below-ankle (e.g., mid-foot) amputation.
7. Above-ankle amputation of contralateral limb.
8. The patient is currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study.
9. Patient has known hypersensitivity or contraindication to materials used during the procedure (cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers) or a known contrast sensitivity that cannot be adequately pre-medicated.
10. Patient cannot be adequately treated with study medications due to known contraindication to aspirin, ADP antagonists such clopidogrel, prasugrel or ticagrelor, or anticoagulants such as heparin or bivalirudin.
11. Patient has had a stroke within the previous 3 months with residual Rankin score of ≥ 2.
12. NYHA Class IV heart failure which may compromise patient's ability to safely undergo a percutaneous procedure, per PI judgment.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treated with Boomerang Catheter	Boomerang Catheter	-

Primary Outcome Measures

Name	Time	Method
Amputation Free Survival (AFS)	6-months	Freedom from above-ankle amputation of the index limb or death (any cause) at 6 months, compared to a literature derived performance goal.

Secondary Outcome Measures

Name	Time	Method
Secondary patency	1 year post index procedure	Time from fistula creation to abandonment (e.g., decision to decline intervention due to occlusion) of the fistula.
Technical success	During index procedure	Successful deployment of the Boomerang Catheter to the anastomosis site, creation of an anastomosis, and confirmation of fistula flow using angiography or Doppler ultrasound immediately post catheter activation.
Procedural success	Immediately post index procedure	confirmation of retrograde fistula flow in the target tibial vein conduit at index procedure completion.
Limb salvage	3 years post index procedure	Freedom from above-ankle amputation of the index limb.
Target wound healing	1, 3, 6, 9-months, and 1-year	Complete or in-process healing of the patient's target wound(s).
Complete wound healing	1, 3, 6, 9-months, and 1-year	Complete healing of all the patient's ischemic wound(s) in the index limb.
Primary patency	1 year post index procedure	Time from fistula creation to the first intervention to maintain or reestablish flow through the fistula or to fistula occlusion.
Primary assisted patency	1 year post index procedure	Time from fistula creation to the first occlusion of the fistula.

Trial Locations

Locations (13)

PIH Whittier Hospital; 🇺🇸 Whittier, California, United States

Advanced Heart and Vein Center; 🇺🇸 Thorton, Colorado, United States

EndoVascular Consultants; 🇺🇸 Wilmington, Delaware, United States

Penn Medicine; 🇺🇸 Philadelphia, Pennsylvania, United States

HOPE Vascular and Podiatry; 🇺🇸 Houston, Texas, United States

First Coast Cardiovascular Institute; 🇺🇸 Jacksonville, Florida, United States

Advanced Endovascular Institute; 🇺🇸 St. Augustine, Florida, United States

Vascular Institute at AMI; 🇺🇸 Galloway, New Jersey, United States

American Endovascular and Amputation Prevention; 🇺🇸 West Orange, New Jersey, United States

Weill Cornell Medical Center; 🇺🇸 New York, New York, United States

Sunrise Vascular; 🇺🇸 Murphy, North Carolina, United States

Advanced Vascular Centers; 🇺🇸 Tigard, Oregon, United States

University of Washington Medicine; 🇺🇸 Seattle, Washington, United States